To determine the clinical performance of a blood-based test for clinically significant (CS) prostate cancer (PCa) (grade group ≥ 2) intended for use in men with prostate serum antigen levels in the 'grey zone' (PSA \< 10 ng/ml). The test quantifies a previously described 3.4 kb mitochondrial DNA (mtDNA) deletion.
Age
45–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Men of screening age (≧45) who are scheduled for prostate needle biopsy due to suspicion of prostate cancer and have a total PSA \< 10ng/ml within the previous 3 months.
Extended Sextant biopsy pattern that must include a minimum of 12 cores. MRI targeted biopsy preferred where available.
Age, total PSA, biopsy pathology, prostate medication history, and ethnicity data must be available;
The index biopsy must occur following and within 16 weeks of blood draw.
You may not be if
Subject does not undergo their prostate biopsy within 16 weeks of collection of pre-biopsy blood sample;
Previous diagnosis of prostate cancer;
Prostate biopsy within the previous 3 months;
Men with a total PSA\>10ng/ml within the previous 3 months;
Provides less than the required amount of blood;
Considered incompetent to provide informed consent;
Does not understand and read language of informed consent;
Age, total PSA, biopsy pathology information, medication history or ethnicity data unavailable;
Males who are not of screening age (\<45);
Subjects whose classification as cancer positive or negative is undetermined following biopsy due to suspicious results such as Atypical Suspicious Acinar Proliferation (ASAP);
Blood collected after index biopsy.
Subject is taking antibiotics at the time of blood collection or has taken antibiotics within the 2 weeks prior to blood collection.
Clareo Health | A Study to Assess Mitomic Prostate Test for Prostate Cancer Screening
